Cited by 2,762Erythropoietin and Anemia TreatmentDialysis and Renal Disease ManagementBiosimilars and Bioanalytical Methods

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease

Open access

Singh, Ajay K., Szczech, Lynda, Tang, Kezhen L., Barnhart, Huiman, Sapp, Shelly, Wolfson, Marsha, Reddan, Donal·2006·New England Journal of Medicine

DOI 10.1056/nejmoa065485

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin deficiency. Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin correction is not defined. METHODS: In this open-label trial, we studied 1432 patients with chronic kidney disease, 715 of whom were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 13.5 g per deciliter and 717 of whom were assigned to receive a dose targeted to achieve a level of 11.3 g per deciliter. The median study duration was 16 months. The primary end point was a composite of death, myocardial infarction, hospitalization for congestive heart failure (without renal replacement therapy), and stroke. RESULTS: A total of 222 composite events occurred: 125 events in the high-hemoglobin group, as compared with 97 events in the low-hemoglobin group (hazard ratio, 1.34; 95% confidence interval, 1.03 to 1.74; P=0.03). There were 65 deaths (29.3%), 101 hospitalizations for congestive heart failure (45.5%), 25 myocardial infarctions (11.3%), and 23 strokes (10.4%). Seven patients (3.2%) were hospitalized for congestive heart failure and myocardial infarction combined, and one patient (0.5%) died after having a stroke. Improvements in the quality of life were similar in the two groups. More patients in the high-hemoglobin group had at least one serious adverse event. CONCLUSIONS: The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g per deciliter) was associated with increased risk and no incremental improvement in the quality of life. (ClinicalTrials.gov number, NCT00211120 [ClinicalTrials.gov].).

Integrity signals

Registry

Crossref · 10.1056/nejmoa065485

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,094
The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
Eknoyan, G., Beck, G. J., Cheung, A. K., Daugirdas, J. T., Greene, T., Kusek, J. W., Allon, M., Bailey, J. L., Delmez, J. A., Depner, T. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021583 · Cited by 1,876
Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis
Jones, M., Ibels, L. S., Schenkel, B., & Zagari, M. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 1,812
Group Sequential Methods with Applications to Clinical Trials
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC eBooks · doi:10.1201/9780367805326 · Cited by 1,339

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 1

Strippoli GF, 2003, Cochrane Database Syst Rev, 1, CD003967

Sorted by citations

Items 601–700 of 1,002

Platelets in Renal Disease
Gomchok, D., Ge, R.-L., & Wuren, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914724 · Cited by 41
Identification and management of preoperative anaemia in adults: A British Society for Haematology Guideline update
Hands, K., Daru, J., Evans, C., Kotzé, A., Lewis, C., Narayan, S., Richards, T., Taylor, C., Timmins, S., & Wilson, A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19440 · Cited by 38
Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention
Kitai, Y., Ozasa, N., Morimoto, T., Bao, B., Furukawa, Y., Nakagawa, Y., Kadota, K., Yanagita, M., Shizuta, S., & Kimura, T. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.029 · Cited by 38
Indoxyl Sulfate Counteracts Endothelial Effects of Erythropoietin Through Suppression of Akt Phosphorylation
Adelibieke, Y., Shimizu, H., Saito, S., Mironova, R., & Niwa, T. (2013) · Circulation Journal · doi:10.1253/circj.cj-12-0884 · Cited by 38
Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study
Tangri, N., Miskulin, D. C., Zhou, J., Bandeen-Roche, K., Michels, W. M., Ephraim, P. L., McDermott, A., Crews, D. C., Scialla, J. J., Sozio, S. M., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu349 · Cited by 38
Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease
Vecchio, L. D., & Locatelli, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1493455 · Cited by 39
On-Glass Integrated SU-8 Waveguide and Amorphous Silicon Photosensor for On-Chip Detection of Biomolecules: Feasibility Study on Hemoglobin Sensing
Buzzin, A., Asquini, R., Caputo, D., & de Cesare, G. (2021) · Sensors · doi:10.3390/s21020415 · Cited by 38
A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps
Lopes, M. B., Tu, C., Zee, J., Guedes, M. H., Pisoni, R. L., Robinson, B. M., Foote, B. S., Hedman, K., James, G., Lopes, A. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79254-6 · Cited by 43
Preoperative Evaluation
Fischer, S. P., Bader, A. M., & Sweitzer, B. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06959-8.00034-0 · Cited by 38
Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study.
Cases, A., Martínez‐Castelao, A., Fort, J., Bonal-Bastons, J., Mp, R., Vallès-Prats, M., Piera, E. C., & Gui, J. M. G. (2014) · PubMed · doi:10.3265/nefrologia.pre2013.dec.12261 · Cited by 39
The Effects of Erythropoietin Dose Titration during High‐Fat Diet‐Induced Obesity
Foskett, A., Alnaeeli, M., Wang, L., Teng, R., & Noguchi, C. T. (2011) · BioMed Research International · doi:10.1155/2011/373781 · Cited by 39
Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice
Schmidt, R. E., Green, K. G., Feng, D., Dorsey, D. A., Parvin, C. A., Lee, J., Xiao, Q., & Brines, M. L. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.09.018 · Cited by 38
Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide
Cernaro, V., Santoro, D., Lacquaniti, A., Costantino, G., Visconti, L., Buemi, A., & Buemi, M. (2016) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s78040 · Cited by 38
Organ‐Protective and Immunomodulatory Effects of Erythropoietin – An Update on Recent Clinical Trials
Sølling, C. G. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00820.x · Cited by 37
Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?
Latini, R., Brines, M. L., & Fiordaliso, F. (2008) · Heart Failure Reviews · doi:10.1007/s10741-008-9084-z · Cited by 37
Hemoglobin Targets for Chronic Kidney Disease Patients with Anemia: A Systematic Review and Meta-analysis
Zhou, J., Wei‐jie, Y., Zhu, N., Zhou, Y., & Wang, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043655 · Cited by 38
Cardiovascular Complications in Diabetic Kidney Disease
Patel, T. V., & Charytan, D. M. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00704.x · Cited by 37
Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g‐Formula to Anemia Management Strategies
Zhang, Y., Young, J. G., Thamer, M., & Hernán, M. Á. (2017) · Health Services Research · doi:10.1111/1475-6773.12718 · Cited by 45
Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease
Finkelstein, F. O., van Nooten, F. E., Wiklund, I. E., Trundell, D., & Cella, D. F. (2018) · Health and Quality of Life Outcomes · doi:10.1186/s12955-018-0933-8 · Cited by 37
Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification
Coyne, D. W., Singh, H. N., Smith, W. T., Giuseppi, A. C., Connarn, J. N., Sherman, M. L., Dellanna, F., Malluche, H. H., & Hruska, K. A. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.08.001 · Cited by 39
How I treat anemia in heart failure
Anand, I. S., & Gupta, P. (2020) · Blood · doi:10.1182/blood.2019004004 · Cited by 38
Anemia in chronic kidney disease
Hazin, M. A. A. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.s1.55 · Cited by 40
Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
Čižman, B., Smith, H. T., Camejo, R. R., Casillas, L., Dhillon, H., Mu, F., Wu, E. Q., Xie, J., Zuckerman, P. R., & Coyne, D. W. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.06.008 · Cited by 39
Experimental modulation of Interleukin 1 shows its key role in chronic kidney disease progression and anemia
Bandach, I., Segev, Y., & Landau, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-85778-2 · Cited by 37
Treatment of anemia in difficult-to-manage patients with chronic kidney disease
Raichoudhury, R., & Spinowitz, B. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.12.006 · Cited by 41
Efficacy and safety of roxadustat for anaemia in dialysis‐dependent and non‐dialysis‐dependent chronic kidney disease patients: A systematic review and meta‐analysis
Zheng, L., Tian, J., Liu, D., Zhao, Y., Fang, X., Zhang, Y., & Liu, Y. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15055 · Cited by 38
Dialysis and fatigue: implications for nurses--a case study analysis.
Horigan, A. E., Rocchiccioli, J. T., & Trimm, D. (2012) · PubMed · Cited by 37
Resolved
Singh, A. K. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009040444 · Cited by 37
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
Saglimbene, V. M., Palmer, S. C., Ruospo, M., Natale, P., Craig, J. C., & Strippoli, G. F. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009904.pub2 · Cited by 36
RETRACTED: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
Provenzano, R., Fishbane, S. N., Szczech, L. A. M., Leong, R., Saikali, K. G., Zhong, M., Lee, T. T., Houser, M. T., Frison, L., Houghton, J., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.12.018 · Cited by 38
Retracted
Darbepoetin for the anaemia of chronic kidney disease
Palmer, S. C., Saglimbene, V. M., Craig, J. C., Navaneethan, S. D., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009297.pub2 · Cited by 37
Hypertension in Small Animal Kidney Disease
Syme, H. M. (2011) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2010.11.002 · Cited by 36
The investigation and treatment of secondary anaemia
Davis, S. L., & Littlewood, T. J. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.10.003 · Cited by 34
Cardiovascular Pathophysiology in Chronic Kidney Disease: Opportunities to Transition from Disease to Health
Tomey, M. I., & Winston, J. A. (2014) · Annals of Global Health · doi:10.1016/j.aogh.2013.12.007 · Cited by 38
The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials
Kang, J., Park, J., Lee, J. M., Park, J. J., & Choi, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.187 · Cited by 37
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare
Wang, C., Kane, R. C., Levenson, M. S., Kelman, J. A., Wernecke, M., Lee, J., Kozlowski, S., Dekmezian, C., Zhang, Z., Thompson, A., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6520 · Cited by 37
Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone
Hanudel, M. R., Wong, S. F., Jung, G., Qiao, B., Gabayan, V. R., Zuk, A., & Ganz, T. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.019 · Cited by 38
Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function
Farrington, D. K., Sang, Y., Grams, M. E., Ballew, S. H., Dunning, S. C., Stempniewicz, N., & Coresh, J. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.07.014 · Cited by 36
Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function
Friend, P. J., Russ, G. R., Oberbauer, R. W., Murgia, M. G., Tufveson, G., Chapman, J. R., Blancho, G., Mota, A., Grandaliano, G., Campistol, J. M., et al. (2007) · Transplant International · doi:10.1111/j.1432-2277.2007.00506.x · Cited by 36
Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese
Kohagura, K., Tomiyama, N., Kinjo, K., Takishita, S., & Iseki, K. (2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0197-z · Cited by 36
Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations
Schmidt, R. J., & Dalton, C. (2007) · Osteopathic Medicine and Primary Care · doi:10.1186/1750-4732-1-14 · Cited by 36
An Ongoing Study of Anemia Correction in Chronic Kidney Disease
Pfeffer, M. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmc066568 · Cited by 36
Correction of Anemia with Erythropoietin in Chronic Kidney Disease (stage 3 or 4): Effects on Cardiac Performance
Pappas, K. D., Gouva, C. D., Katopodis, K. P., Nikolopoulos, P. M., Korantzopoulos, P. G., Michalis, L. K., Goudevenos, J. A., & Siamopoulos, K. C. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6075-6 · Cited by 36
A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern Network on Adverse Reactions (SONAR)
Spiegel, D., Macdougall, I. C., Norris, L. B., Qureshi, Z. P., Sartor, O. A., Lai, S. Y., Tallman, M. S., Raisch, D. W., Smith, S. W., Silver, S. M., et al. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1328884 · Cited by 35
Resistance to Erythropoiesis Stimulating Agents in Patients Treated with Online Hemodiafiltration and Ultrapure Low-Flux Hemodialysis: Results from a Randomized Controlled Trial (CONTRAST)
van der Weerd, N. C., den Hoedt, C. H., Blankestijn, P. J., Bots, M. L., van den Dorpel, M. A., Levesque, R. L., Mazairac, A. H. A., Nubé, M. J., Penne, E. L., ter Wee, P. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094434 · Cited by 35
Erythropoietin and the heart: facts and perspectives
Mastromarino, V., Volpe, M., Musumeci, B., Autore, C., & Conti, E. (2010) · Clinical Science · doi:10.1042/cs20100305 · Cited by 35
Erythropoietin Receptor Signaling Mitigates Renal Dysfunction-Associated Heart Failure by Mechanisms Unrelated to Relief of Anemia
Ogino, A., Takemura, G., Kawasaki, M., Tsujimoto, A., Kanamori, H., Li, L., Goto, K., Maruyama, R., Kawamura, I., Takeyama, T., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.068 · Cited by 35
Comparison of the Safety and Efficacy of 3 Iron Sucrose Iron Maintenance Regimens in Children, Adolescents, and Young Adults With CKD: A Randomized Controlled Trial
Goldstein, S. L., Morris, D., & Warady, B. A. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.10.019 · Cited by 35
Threshold Haemoglobin Levels and the Prognosis of Stable Coronary Disease: Two New Cohorts and a Systematic Review and Meta-Analysis
Shah, A. D., Nicholas, O., Timmis, A., Feder, G. S., Abrams, K. R., Chen, R., Hingorani, A. D., & Hemingway, H. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000439 · Cited by 37
Distinct immunologic effects of different intravenous iron preparations on monocytes
Fell, L. H., Zawada, A. M., Rogacev, K. S., Seiler, S., Fliser, D., & Heine, G. H. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft524 · Cited by 34
Posttransplant anemia in solid organ recipients
Blosser, C. D., & Bloom, R. D. (2010) · Transplantation Reviews · doi:10.1016/j.trre.2010.01.006 · Cited by 36
International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study
Fuller, D. S., Bieber, B. A., Pisoni, R. L., Li, Y., Morgenstern, H., Akizawa, T., Jacobson, S. H., Locatelli, F., Port, F. K., & Robinson, B. M. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060673 · Cited by 35
Erythropoiesis-stimulating Agents in Critically Ill Trauma Patients
French, C., Glassford, N. J., Gantner, D. C., Higgins, A. M., Cooper, D. J., Nichol, A., Skrifvars, M. B., Imberger, G. L., Presneill, J., Bailey, M., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001746 · Cited by 35
Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis
Rheault, M. N., Molony, J. T., Nevins, T. E., Herzog, C. A., & Chavers, B. M. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.013 · Cited by 35
Factors affecting the transition of acute kidney injury to chronic kidney disease: Potential mechanisms and future perspectives
Ogbadu, J., Singh, G., & Aggarwal, D. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172711 · Cited by 38
The Top 10 Things Nephrologists Wish Every Primary Care Physician Knew
Paige, N. M., & Nagami, G. T. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.180 · Cited by 35
Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial
Lau, J. H., Gangji, A. S., Rabbat, C. G., & Brimble, K. S. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq330 · Cited by 34
Hemodialysis in children with end-stage renal disease
Müller, D. N., & Goldstein, S. L. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.124 · Cited by 36
Performance Measurement in Chronic Kidney Disease
Smith, K. A., & Hayward, R. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111152 · Cited by 35
Predictors of quality of life of hemodialysis patients in India
Veerappan, I., Arvind, R., & Ilayabharthi, V. (2011) · Indian Journal of Nephrology · doi:10.4103/0971-4065.91185 · Cited by 35
Anemia and Cardiovascular Risk in the Patient with Kidney Disease
Fishbane, S. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.03.005 · Cited by 35
Anaemia is common and predicts mortality in diabetic nephropathy
Joss, N., Patel, R., Paterson, K., Simpson, K., Perry, C. G., & Stirling, C. (2007) · QJM · doi:10.1093/qjmed/hcm080 · Cited by 35
Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease
Yılmaz, M. İ., Sönmez, A., Sağlam, M., Güleç, M., Kılıç, S., Eyileten, T., Çağlar, K., Oğuz, Y., Vural, A., Yenicesu, M., et al. (2009) · Kidney International · doi:10.1038/ki.2009.63 · Cited by 36
What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?
Besarab, A., Frinak, S., & Yee, J. (2009) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2008.12.007 · Cited by 34
Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study
Lamerato, L. E., James, G., van Haalen, H., Hedman, K., Sloand, J. A., Tang, A., Wittbrodt, E. T., & Yee, J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02778-8 · Cited by 36
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
Suttorp, M., Hoekstra, T., Rotmans, J. I., Ott, I., Mittelman, M., Krediet, R. T., & Dekker, F. W. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-200 · Cited by 33
Prevalence of Ventricular Arrhythmia and Its Associated Factors in Nondialyzed Chronic Kidney Disease Patients
Bonato, F. O. B., Lemos, M. M., Cassiolato, J. L., & Canziani, M. E. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066036 · Cited by 34
Erythropoietin: The swinging pendulum
Oster, H. S., Neumann, D., Hoffman, M. A., & Mittelman, M. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.04.017 · Cited by 33
High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation
Hafer, C., Becker, T., Kielstein, J. T., Bahlmann, E., Schwarz, A., Grinzoff, N., Drzymala, D., Bonnard, I., Richter, N., Lehner, F., et al. (2011) · Kidney International · doi:10.1038/ki.2011.349 · Cited by 34
Clinical Studies of Interventions to Mitigate Cardiovascular Risk in Peritoneal Dialysis Patients.
Jegatheesan, D., Cho, Y., & Johnson, D. W. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.007 · Cited by 31
SGLT2 inhibitors – a potential treatment for Alport syndrome
Mabillard, H. R., & Sayer, J. A. (2020) · Clinical Science · doi:10.1042/cs20191276 · Cited by 36
Posttransplant anemia: the role of sirolimus
Fishbane, S., Cohen, D. J., Coyne, D. W., Djamali, A., Singh, A. K., & Wish, J. B. (2009) · Kidney International · doi:10.1038/ki.2009.231 · Cited by 34
Chronic kidney disease, heart failure and anemia
Virani, S., Khosla, A., & Levin, A. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)71026-2 · Cited by 36
Anemia: An independent predictor of death and hospitalizations among elderly patients with atrial fibrillation
Sharma, S., Gage, B. F., Deych, E., & Rich, M. W. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.03.009 · Cited by 34
The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data
Pollak, V. E., Lorch, J. A., Shukla, R., & Satwah, S. (2009) · BMC Nephrology · doi:10.1186/1471-2369-10-6 · Cited by 34
Therapeutic effect of erythropoietin in patients with traumatic brain injury: a meta-analysis of randomized controlled trials
Liu, W., Wen, L., Xie, T., Wang, H., Gong, J., & Yang, X.-F. (2016) · Journal of neurosurgery · doi:10.3171/2016.4.jns152909 · Cited by 34
Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients
Schlieper, G., Hristov, M., Brandenburg, V. M., Krüger, T., Westenfeld, R., Mahnken, A. H., Yagmur, E., Boecker, G., Heussen, N. M., Gladziwa, U., et al. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn103 · Cited by 34
Improving efficiency and value in health care Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice
Bhandari, S., & Naudeer, S. (2008) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2007.00932.x · Cited by 33
Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing Therapies
Wish, J. B., & Coyne, D. W. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1371 · Cited by 34
Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease
Warady, B. A., & Silverstein, D. M. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2557-x · Cited by 33
Evolving Statistical Methods to Facilitate Evaluation of the Causal Association Between Erythropoiesis-Stimulating Agent Dose and Mortality in Nonexperimental Research: Strengths and Limitations
Bradbury, B. D., Brookhart, M. A., Winkelmayer, W. C., Critchlow, C. W., Kilpatrick, R. D., Joffe, M. M., Feldman, H. I., Acquavella, J., Wang, O., & Rothman, K. J. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.05.010 · Cited by 32
Investigational therapies for renal disease-induced anemia
Schmid, H., & JELKMANN, W. E. B. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1182981 · Cited by 33
Risk of massive blood product requirement in cardiac surgery
Huang, D., Chen, C., Ming, Y., Liu, J., Zhou, L., Zhang, F., Yan, M., & Du, L. (2019) · Medicine · doi:10.1097/md.0000000000014219 · Cited by 33
The association of cadmium and lead exposures with red cell distribution width
Peters, J. L., Perry, M. J., McNeely, E., Wright, R. O., Heiger‐Bernays, W., & Weuve, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245173 · Cited by 34
2008 JSDT “Guideline for Renal Anemia in Chronic Kidney Disease”
(2008) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.41.661 · Cited by 33
Quality of Life in Patients Undergoing Hemodialysis
Mollaoğlu, M. (2013) · InTech eBooks · doi:10.5772/52277 · Cited by 35
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
Inrig, J. K., Bryskin, S. K., Patel, U. D., Arcasoy, M. O., & Szczech, L. A. M. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-67 · Cited by 33
Meeting KDOQI Guideline Goals at Hemodialysis Initiation and Survival during the First Year
Slinin, Y., Guo, H., Gilbertson, D. T., Mau, L., Ensrud, K. E., Rector, T. S., Collins, A. J., & Ishani, A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01320210 · Cited by 33
High Prevalence of Anemia in Predialysis Patients in Enugu, Nigeria
Ijoma, C. K., Ulasi, I., Ijoma, U. N., & Ifebunandu, N. A. (2010) · Nephrology Research & Reviews · doi:10.4081/nr.2010.e14 · Cited by 33
Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects.
Provatopoulou, S., & Ziroyiannis, P. (2011) · Europe PMC (PubMed Central) · Cited by 33
Roxadustat and Anemia of Chronic Kidney Disease
Kaplan, J. (2019) · New England Journal of Medicine · doi:10.1056/nejme1908978 · Cited by 33
Conversion of Darbepoetin to Low Doses of CERA Maintains Hemoglobin Levels in Non-Dialysis Chronic Kidney Disease Patients
Minutolo, R., Zamboli, P., Chiodini, P., Mascia, S., Vitiello, S., Stanzione, G., Bertino, V., Conte, G., & Nicola, L. D. (2010) · Blood Purification · doi:10.1159/000321486 · Cited by 32
Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
Gilbertson, D. T., Peng, Y., Arneson, T. J., Dunning, S. C., & Collins, A. J. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-44 · Cited by 32
Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome—a randomized prospective pilot trial
Pape, L., Ahlenstiel, T., Kreuzer, M., Drube, J., Froede, K., Franke, D., Ehrich, J. H. H., & Haubitz, M. (2008) · Pediatric Nephrology · doi:10.1007/s00467-008-1087-4 · Cited by 32
Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review
Pérgola, P. E., Pecoits‐Filho, R., Winkelmayer, W. C., Spinowitz, B., Rochette, S., Thompson‐Leduc, P., Lefèbvre, P., Shafai, G., Bozas, A., Sanon, M., et al. (2019) · PharmacoEconomics - Open · doi:10.1007/s41669-019-0132-5 · Cited by 32
Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study
Eisenga, M. F., de Jong, M. A., van der Meer, P., Leaf, D. E., Huls, G. A., Nolte, I. M., Gaillard, S., Bakker, S. J. L., & de Borst, M. H. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002818 · Cited by 34
The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis
Zheng, Q., Yang, H., Fu, X., Huang, Y., Wei, R., Wang, Y., Liu, Y., & Liu, W. J. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa110 · Cited by 34
Iron Deficiency in CKD Without Concomitant Anemia
Wish, J. B., Anker, S. D., Butler, J., Cases, A., Stack, A. G., & Macdougall, I. C. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.07.032 · Cited by 34
Caring for the pregnant kidney transplant recipient
Concepcion, B. P., & Schaefer, H. M. (2011) · Clinical Transplantation · doi:10.1111/j.1399-0012.2011.01492.x · Cited by 32
Chronic kidney disease and cardiovascular risk
Yerram, P., Karuparthi, P. R., Hesemann, L. E., Horst, J. A., & Whaley‐Connell, A. T. (2007) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2007.01.010 · Cited by 34

Authors: Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D.
Affiliations: Brigham and Women's Hospital (US)
Duke Medical Center (US)
Duke University (US)
Duke Clinical Research Institute (US)
Ollscoil na Gaillimhe – University of Galway (IE)
ORCID: Singh, Ajay K.
Barnhart, Huiman
Reddan, Donal
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2006-11-16
Volume: 355
Issue: 20
Pages: 2085-2098
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa065485
OpenAlex: W2040029744
Cited by: 2,762
References: 32
Citations by year: 2026: 57 · 2025: 64 · 2024: 73 · 2023: 95 · 2022: 95 · 2021: 116 · 2020: 121 · 2019: 116 · 2018: 92 · 2017: 101 · 2016: 108 · 2015: 114 · 2014: 155 · 2013: 176 · 2012: 182
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords: epoetin alfa, chronic kidney disease, anemia of chronic kidney disease, hemoglobin target, erythropoietin deficiency, cardiovascular events, congestive heart failure, myocardial infarction, stroke, mortality, quality of life, adverse events
MeSH terms: Epoetin Alfa, Aged, Anemia, Erythropoietin, Female, Glomerular Filtration Rate, Heart Failure, Hematinics, Hemoglobins, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Recombinant Proteins, Survival Analysis, Stroke, Renal Insufficiency, Chronic, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks